Tepmetko (Tepotinib)

Save over 60% buying from Insulinhub.

Manufacturer of all European product: Merck Healthcare KGaA Frankfurter Strasse 250 64293 Darmstadt Germany

Information about Tepmetko (Tepotinib)

Tepmetko is a prescription medication that contains tepotinib as its active ingredient. Tepotinib is an oral tyrosine kinase inhibitor designed to treat certain types of cancer, specifically targeting mutations in the MET gene. It is used in the treatment of non-small cell lung cancer (NSCLC) that has a MET exon 14 skipping mutation, a genetic alteration that can drive the development and spread of cancer. Tepmetko works by inhibiting the MET receptor, preventing tumor growth and spread.

Product Highlights

• Tepmetko is primarily used to treat adults with advanced or metastatic non-small cell lung cancer (NSCLC) that has a MET exon 14 skipping mutation. This genetic mutation can make the cancer more aggressive and resistant to other treatments.
• It is indicated for the treatment of metastatic non-small cell lung cancer in patients who have a MET exon 14 mutation, helping to control the progression of the disease and potentially improve survival.

Key Ingredient

• Tepotinib

Key Benefits

• Tepmetko offers a targeted therapy that specifically inhibits the MET receptor, blocking the pathways that promote cancer cell growth in individuals with MET-driven tumors.
• It is particularly effective in treating NSCLC with a MET exon 14 mutation, a mutation that is often associated with aggressive disease progression and poor response to traditional therapies.
• Tepmetko can help slow the progression of non-small cell lung cancer, leading to improved quality of life and potentially longer survival for patients with this specific genetic alteration.
• As an oral medication, Tepmetko provides a more convenient option for patients compared to intravenous therapies.

Direction of Use

• The recommended dose of Tepmetko is 450 mg once daily, taken with or without food. It should be taken at the same time each day for consistent blood levels.
• Tepmetko tablets should be swallowed whole with a glass of water. The tablets should not be crushed, divided, or chewed. 
• If you miss a dose, take it as soon as you can, unless it's almost time for your next dose. If that happens, skip the missed dose and continue with your regular dosing schedule. Do not take two doses at once.
• During treatment, patients may need regular monitoring for liver function and other blood parameters as directed by the healthcare provider.

Safety Concerns

• Tepmetko can cause liver toxicity, so liver function should be monitored regularly. Patients should report symptoms such as yellowing of the skin or eyes (jaundice), dark urine, or pain in the upper right side of the abdomen.
• There is a risk of interstitial lung disease (ILD) or pneumonitis, which can be serious and life-threatening. Patients should be monitored for signs of lung problems such as coughing, difficulty breathing, or chest pain.
• Tepmetko may cause nausea, vomiting, and diarrhea, which should be managed as recommended by the healthcare provider.
• Tepmetko has been associated with elevated blood pressure (hypertension). Blood pressure should be monitored regularly throughout the treatment. 
• Tepmetko can cause QT interval prolongation on the ECG, which can lead to abnormal heart rhythms. Monitoring of heart function may be necessary.
• Tepmetko is not recommended during pregnancy due to the potential risk to the fetus. It should also be avoided while breastfeeding, as it may be excreted in breast milk. 

Avoid Tepmetko (Tepotinib) If

• If you have a known allergy to tepotinib or any of its ingredients, avoid using the medication.
• Tepmetko should be avoided in patients with severe liver dysfunction due to the risk of worsening liver toxicity.
• If you have a history of interstitial lung disease (ILD) or pneumonitis, Tepmetko may not be suitable for you as it may exacerbate these conditions.
• Tepmetko is not recommended for use during pregnancy as it can harm a developing fetus. This medication should be avoided by women who are pregnant or planning to become pregnant. 
• Tepmetko should not be used while breastfeeding, as it may pass into breast milk and affect the nursing infant.
• If you have a history of severe heart problems, particularly related to QT prolongation, Tepmetko should be avoided or used with caution under close supervision.